Cognition Therapeutics
CGTX | NASDAQ
$0.64
-$0.04 (-5.85%)
At close: Nov 16, 2026, 4:00 PM ET
$0.64
$0.00 (-0.47%)
After-hours:
Nov 16, 2026, 7:26 PM ET
Cognition Therapeutics Company Profile
Company profile explainedCompany Profile
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Key Executives
| Name | Position |
|---|---|
| Lisa Ricciardi | Chief Executive Officer, President & Director |
| John Brendan Doyle | Chief Financial Officer |
| Anita Cornet | Head of Quality |
| Anthony O. Caggiano | Chief Medical Officer |
| Bobby Horn | Corporate Controller |
| Steven A. Weissman | Vice President & Head of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2026 | 8-K | Current Report |
| Aug 07, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jun 24, 2026 | 8-K | Current Report |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 18, 2026 | 8-K | Current Report |
Cognition Therapeutics
| Country | United States |
| IPO Date | Oct 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Lisa Ricciardi |
Contact Details
2500 Westchester Avenue Purchase,
New York 10577 United States
Stock Details
| Ticker Symbol | CGTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001455365 |
| CUSIP Number | 19243B102 |
| ISIN Number | US19243B1026 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove CGTX